Literature DB >> 28405913

In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Xia Wen1, Melanie S Joy2, Lauren M Aleksunes3,4.   

Abstract

PURPOSE: Multidrug resistance-associated protein 2 (MRP2/ABCC2) is an efflux pump that removes drugs and chemicals from cells. We sought to characterize the expression, trafficking and in vitro activity of seven single nucleotide polymorphisms (SNPs) in the ABCC2 gene.
METHODS: ABCC2 SNPs were generated using site-directed mutagenesis and stably expressed in Flp-In HEK293 cells, which allows targeted insertion of transgenes within the genome. Total and cell surface expression of MRP2 as well as accumulation of substrates (calcein AM and 5(6)-carboxy-2',7'-dichlorofluorescein diacetate, CDCF) were quantified in cells or inverted membrane vesicles expressing wild-type (WT) or variant forms.
RESULTS: The cell surface expression of the C-24T-, G1249A-, G3542T-, T3563A-, C3972T- and G4544A-MRP2 variants was similar to WT-MRP2. While expression was similar, transport of calcein AM was enhanced in cells expressing the G3542T-, T3563A-, C3972T-, and G4544A-MRP2 variants. By comparison, cells expressing the C2366T-MRP2 variant had 40-50% lower surface expression, which increased the accumulation of calcein AM up to 3-fold. Accumulation of CDCF in inverted membrane vesicles expressing the C2366T-MRP2 variant was also reduced by 50%. In addition, the G1249A-MRP2 variant had decreased transport of CDCF.
CONCLUSIONS: Taken together, these data demonstrate that genetic variability in the ABCC2 gene influences the in vitro expression, trafficking, and transport activity of MRP2.

Entities:  

Keywords:  ABCC2; MRP2; SNP; transporter; variant

Mesh:

Substances:

Year:  2017        PMID: 28405913      PMCID: PMC5500460          DOI: 10.1007/s11095-017-2160-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.

Authors:  Sierk Haenisch; Karen May; Danilo Wegner; Amke Caliebe; Ingolf Cascorbi; Werner Siegmund
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

2.  Identification of regions required for apical membrane localization of human multidrug resistance protein 2.

Authors:  Paul E Bandler; Christopher J Westlake; Caroline E Grant; Susan P C Cole; Roger G Deeley
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

3.  Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.

Authors:  S Toh; M Wada; T Uchiumi; A Inokuchi; Y Makino; Y Horie; Y Adachi; S Sakisaka; M Kuwano
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

4.  A high throughput in vitro mrp2 assay to predict in vivo biliary excretion.

Authors:  Federico Colombo; Catherine Armstrong; Jianmin Duan; Nathalie Rioux
Journal:  Xenobiotica       Date:  2011-10-02       Impact factor: 1.908

5.  Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2.

Authors:  S Ryu; T Kawabe; S Nada; A Yamaguchi
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

6.  Functional analysis of SNPs variants of BCRP/ABCG2.

Authors:  Chihiro Kondo; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Daisuke Kobayashi; Ichiro Ieiri; Kazunori Mine; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

7.  Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.

Authors:  C C Paulusma; M A van Geer; R Evers; M Heijn; R Ottenhoff; P Borst; R P Oude Elferink
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

8.  Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.

Authors:  Anneke N Werk; Henrike Bruckmueller; Sierk Haenisch; Ingolf Cascorbi
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

9.  Interaction of digitalis-like compounds with p-glycoprotein.

Authors:  Elnaz Gozalpour; Hanneke G M Wittgen; Jeroen J M W van den Heuvel; Rick Greupink; Frans G M Russel; Jan B Koenderink
Journal:  Toxicol Sci       Date:  2012-10-26       Impact factor: 4.849

10.  Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2.

Authors:  Masakazu Hirouchi; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Ichiro Ieiri; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

View more
  9 in total

1.  Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
Journal:  Oncotarget       Date:  2018-01-10

2.  A double-Flp-in method for stable overexpression of two genes.

Authors:  Ole Jensen; Salim Ansari; Lukas Gebauer; Simon F Müller; Kira A A T Lowjaga; Joachim Geyer; Mladen V Tzvetkov; Jürgen Brockmöller
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

3.  Enhanced hepatic differentiation in the subpopulation of human amniotic stem cells under 3D multicellular microenvironment.

Authors:  Kinji Furuya; Yun-Wen Zheng; Daisuke Sako; Kenichi Iwasaki; Dong-Xu Zheng; Jian-Yun Ge; Li-Ping Liu; Tomoaki Furuta; Kazunori Akimoto; Hiroya Yagi; Hiromi Hamada; Hiroko Isoda; Tatsuya Oda; Nobuhiro Ohkohchi
Journal:  World J Stem Cells       Date:  2019-09-26       Impact factor: 5.326

4.  Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.

Authors:  Maud Maillard; Christine Chevreau; Félicien Le Louedec; Manon Cassou; Caroline Delmas; Laure Gourdain; Jean-Yves Blay; Didier Cupissol; Emmanuelle Bompas; Antoine Italiano; Nicolas Isambert; Corinne Delcambre-Lair; Nicolas Penel; François Bertucci; Cécile Guillemet; Julien Plenecassagnes; Stéphanie Foulon; Étienne Chatelut; Axel Le Cesne; Fabienne Thomas
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

5.  Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.

Authors:  Danyang Li; Yingcheng Yao; Yuhan Rao; Xinyu Huang; Li Wei; Zhimei You; Guo Zheng; Xiaoli Hou; Yu Su; Zac Varghese; John F Moorhead; Yaxi Chen; Xiong Z Ruan
Journal:  J Exp Clin Cancer Res       Date:  2022-03-30

6.  Case Report: Three novel pathogenic ABCC2 mutations identified in two patients with Dubin-Johnson syndrome.

Authors:  Chenyu Zhao; Xiaoliu Shi; Yonghong Zhang; Hui Huang
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

Review 7.  Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.

Authors:  Loraine Kay D Cabral; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

8.  In vitro Transport Ability of ABCC2 (G1249A) Polymorphic Variant Towards Anticancer Drugs.

Authors:  Guo Lian; Jia Yuan; Yuan Gao
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

9.  A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.

Authors:  Lina Wu; Yanmeng Li; Yi Song; Donghu Zhou; Siyu Jia; Anjian Xu; Wei Zhang; Hong You; Jidong Jia; Jian Huang; Xiaojuan Ou
Journal:  Orphanet J Rare Dis       Date:  2020-03-18       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.